Quercis Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   0 Diseases  2 Products   9 Trials   112 News 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kinisoquin (isoquercetin) / Quercis Pharma
CATIQ P3, NCT06861088: The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer

Not yet recruiting
3
340
NA
Isoquercetin, Placebo
Quercis Pharma AG
Venous Thromboembolism, Metastatic Pancreatic Cancer
07/26
12/26
NCT04733651: Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19

Not yet recruiting
2
250
NA
Hospital standard of care for COVID-19, Isoquercetin
Nepal Health Research Council
Covid19
05/21
08/21
NCT04536090: Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Withdrawn
2
150
NA
Isoquercetin (IQC-950AN), IQC-950AN
Institut de Recherches Cliniques de Montreal, Pharmascience Inc., SCiAN Services, Inc., Quercis Pharma AG
COVID-19
12/22
06/23
NCT04622865 / 2020-001635-27: Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Recruiting
2
200
Europe
Masitinib, AB1010, Isoquercetin, quercetin-3-O-glucoside, isotrifoliin, Best Supportive Care, BSC
AB Science
SARS-CoV 2, COVID-19, Coronavirus Disease 2019
12/23
12/23
ACTRN12617001202358: The effect of a flavonoid food additive on blood vessel function

Recruiting
N/A
25
 
University of Western Australia, San-Ei Gen F.F.I.
high blood pressure, high cholesterol, high blood sugar, obesity
 
 
Q-Force (quercetin) / Quercis Pharma, Temple University
polyphenols, NCT06003270: Biological Effects of Quercetin in COPD Phase II

Recruiting
2
30
US
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Temple University, National Center for Complementary and Integrative Health (NCCIH), Quercegen Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
02/25
07/25
NCT02013440: Beneficial Effects of Quercetin in COPD - a Preliminary Clinical Trial

Not yet recruiting
1/2
99
US
Quercetin 500 mg, Q Force, Quercetin 1000 mg, Placebo, Quercetin 2000 mg
University of Michigan, National Institutes of Health (NIH), Quercegen Pharmaceuticals LLC
Chronic Obstructive Pulmonary Disease
12/14
12/14
NCT03989271: Biological Effects of Quercetin in COPD

Recruiting
1/2
29
US
Quercetin, placebo
Temple University, National Institutes of Health (NIH), Quercegen Pharmaceuticals, National Center for Complementary and Integrative Health (NCCIH)
Chronic Obstructive Pulmonary Disease
05/24
07/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kinisoquin (isoquercetin) / Quercis Pharma
CATIQ P3, NCT06861088: The Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer

Not yet recruiting
3
340
NA
Isoquercetin, Placebo
Quercis Pharma AG
Venous Thromboembolism, Metastatic Pancreatic Cancer
07/26
12/26
NCT04733651: Study to Investigate the Clinical Efficacy of Isoquercetin in Patients With COVID-19

Not yet recruiting
2
250
NA
Hospital standard of care for COVID-19, Isoquercetin
Nepal Health Research Council
Covid19
05/21
08/21
NCT04536090: Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

Withdrawn
2
150
NA
Isoquercetin (IQC-950AN), IQC-950AN
Institut de Recherches Cliniques de Montreal, Pharmascience Inc., SCiAN Services, Inc., Quercis Pharma AG
COVID-19
12/22
06/23
NCT04622865 / 2020-001635-27: Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Recruiting
2
200
Europe
Masitinib, AB1010, Isoquercetin, quercetin-3-O-glucoside, isotrifoliin, Best Supportive Care, BSC
AB Science
SARS-CoV 2, COVID-19, Coronavirus Disease 2019
12/23
12/23
ACTRN12617001202358: The effect of a flavonoid food additive on blood vessel function

Recruiting
N/A
25
 
University of Western Australia, San-Ei Gen F.F.I.
high blood pressure, high cholesterol, high blood sugar, obesity
 
 
Q-Force (quercetin) / Quercis Pharma, Temple University
polyphenols, NCT06003270: Biological Effects of Quercetin in COPD Phase II

Recruiting
2
30
US
Quercetin 1000 mg, Quercetin 500 MG, Placebo
Temple University, National Center for Complementary and Integrative Health (NCCIH), Quercegen Pharmaceuticals
Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis With Airway Obstruction
02/25
07/25
NCT02013440: Beneficial Effects of Quercetin in COPD - a Preliminary Clinical Trial

Not yet recruiting
1/2
99
US
Quercetin 500 mg, Q Force, Quercetin 1000 mg, Placebo, Quercetin 2000 mg
University of Michigan, National Institutes of Health (NIH), Quercegen Pharmaceuticals LLC
Chronic Obstructive Pulmonary Disease
12/14
12/14
NCT03989271: Biological Effects of Quercetin in COPD

Recruiting
1/2
29
US
Quercetin, placebo
Temple University, National Institutes of Health (NIH), Quercegen Pharmaceuticals, National Center for Complementary and Integrative Health (NCCIH)
Chronic Obstructive Pulmonary Disease
05/24
07/25

Download Options